Powder: -20°C for 3 years | In solvent: -80°C for 1 year
JAK3-IN-1 is a selective and orally active JAK3 inhibitor (IC50: 4.8 nM). JAK3-IN-1 displays over 180-fold more selective for JAK3 than JAK1 (IC50: 896 nM) and JAK2 (IC50: 1050 nM).
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | 6-8 weeks | $ 228.00 | |
25 mg | 6-8 weeks | $ 766.00 | |
50 mg | 6-8 weeks | $ 996.00 | |
100 mg | 6-8 weeks | $ 1,390.00 |
Description | JAK3-IN-1 is a selective and orally active JAK3 inhibitor (IC50: 4.8 nM). JAK3-IN-1 displays over 180-fold more selective for JAK3 than JAK1 (IC50: 896 nM) and JAK2 (IC50: 1050 nM). |
Targets&IC50 | JAK2:1050 nM, JAK1:896 nM, TTK:49 nM, BTK:794 nM, JAK3:4.8 nM, ITK:1070 nM |
In vitro | JAK3-IN-1 most potently inhibits JAK3 and identified fms-related tyrosine kinase 3 (FLT3) and several tyrosine protein kinase (TEC)-family kinases as being potential off-targets. JAK3-IN-1 selectively inhibits the proliferation of JAK3-dependent Ba/F3 cells (IC50 = 69 nM) relative to other JAK-dependent Ba/F3 cells, for which there was no antiproliferative effect at concentrations below 3.0 μM. JAK3-IN-1 displays very low inhibition scores for other JAKs and wild-type (WT) EGFR, which is consistent with the over 180-fold higher IC50s against EGFRWT and TYK2 (IC50s =409 nM, > 10000 respectively). JAK3-IN-1 possesses over 165-fold higher IC50s for BTK or ITK (IC50s = 794 and 1070 nM respectively). JAK3-IN-1( 0-5 μM; 3 hours; BMDMs cells) treatment fullly inhibits IL-4 induced p-STAT6 at a concentration of 500 nM and only partially inhibits IFNβ-induced p-STAT1 at a concentration of 5.0 μM. Enzymatic assays using the Z'-lyte or LanthaScreen formats confirmed enzymatic inhibition of FLT3 (IC50 = 13 nM), TTK protein kinase (TTK, IC50 = 49 nM), BLK proto-oncogene (BLK, IC50 = 157 nM) and tyrosine protein kinase TXK (TXK, IC50 = 36 nM) [1]. |
In vivo | The numbers of B or T lymphocytes in the tumor-bearing lungs and spleens of treated mice is not affected, after oral administration with JAK3-IN-1(Compound 9) (75 mpk, QD) for 8 days, however, the number of NK cells is reduced. JAK3-IN-1 displays reasonable pharmacokinetic properties, with moderate T1/2 of 1.4 h, area under the curve (AUC) value of 795 ng*hr/mL following a 10 mg/Kg oral dose and good oral bioavailability of 66% [1]. |
Molecular Weight | 508.02 |
Formula | C26H30ClN7O2 |
CAS No. | 1805787-93-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 47 mg/mL (92.52 mM)
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
JAK3-IN-1 1805787-93-2 Others JAK-3-IN-1 JAK3 IN 1 JAK3IN1 inhibitor inhibit